Learn How Alzheimer’s Creeped Into My Brain
Alzheimer's doesn't begin with memory loss. It begins silently 20 to 30 years earlier as changes in beta-amyloid, toxic oligomers, inflammation, and tau gradually damage the brain. This article explains the modern science behind Alzheimer's in clear, understandable language and shows how new blood tests, biomarkers, and treatments like Leqembi are transforming diagnosis, and offering hope for the future.
Leqembi Does Much More Than Remove Plaque
Most people think Leqembi simply removes amyloid plaque. The science tells a much bigger story. Researchers now believe tiny beta-amyloid oligomers begin damaging synapses and disrupting the brain's glutamate-GABA balance years before plaques appear. Understanding how Leqembi targets these toxic proteins changed the way I think about Alzheimer's disease, and why early treatment matters.
How Leqembi’s Multi-Target Strategy Fights Alzheimer’s
For decades, Alzheimer's treatments could do little more than ease symptoms while the disease continued its relentless attack on the brain. Leqembi represents a different approach. Rather than simply treating the consequences of Alzheimer's, it targets the disease itself by attaching to harmful beta-amyloid proteins at multiple stages of their development—from the smallest, most toxic clusters to fully formed plaques. By interrupting this destructive process early and continuing to remove existing amyloid, Leqembi gives the brain a better opportunity to protect neurons, preserve memory, and maintain the connections that define who we are. Understanding why this matters begins with understanding how Alzheimer's damages the brain.